Acquired by Centene in January 2022
MGLN - Magellan Health, Inc.
NASDAQ
->
Healthcare
->
Healthcare Plans
Phoenix,
United States
Type: Equity
MGLN price evolution
MGLN
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1038.46 | $678.51 | $456.31 | $1144.45 |
| Short term investments | $155.52 | $325.58 | $625.6 | $140.85 |
| Net receivables | $827.17 | $827 | $793.5 | $743.5 |
| Inventory | $39.83 | $38.79 | $46.39 | $43.33 |
| Total current assets | $2204.42 | $2015.03 | $2023.26 | $2156.4 |
| Long term investments | $2.98 | $4.83 | $2.61 | |
| Property, plant & equipment | $137.05 | $141.63 | $142.08 | $136.74 |
| Goodwill & intangible assets | $930.98 | $938.24 | $945.46 | $953.47 |
| Total noncurrent assets | $1149.03 | $1202.9 | $1213.24 | $1203.46 |
| Total investments | $155.52 | $328.57 | $630.43 | $143.46 |
| Total assets | $3353.45 | $3217.93 | $3236.51 | $3359.86 |
| Current liabilities | ||||
| Accounts payable | $358.95 | $279.85 | $266.34 | $249.23 |
| Deferred revenue | ||||
| Short long term debt | $3.21 | $3.18 | $6.54 | $6.52 |
| Total current liabilities | $756.02 | $629.63 | $662.21 | $737.58 |
| Long term debt | $516.37 | $521.52 | $526.68 | $631.86 |
| Total noncurrent liabilities | $624.27 | $630.8 | $631.43 | $719.24 |
| Total debt | $519.58 | $524.69 | $533.23 | $638.38 |
| Total liabilities | $1380.29 | $1260.43 | $1293.64 | $1456.82 |
| Shareholders' equity | ||||
| Retained earnings | $1885.19 | $1884.29 | $1884.96 | $1857.13 |
| Other shareholder equity | -$0.04 | -$0.02 | -$0.2 | -$0.2 |
| Total shareholder equity | $1933.9 | $1923.82 | $1909.57 | $1869.97 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1144.45 | $325.25 | $272.31 | $398.73 |
| Short term investments | $140.85 | $334.49 | $382.58 | $310.58 |
| Net receivables | $743.5 | $890.07 | $756.06 | $660.77 |
| Inventory | $43.33 | $44.96 | $40.82 | $40.95 |
| Total current assets | $2156.4 | $1673.04 | $1547.17 | $1483.35 |
| Long term investments | $2.61 | $10.67 | $3.16 | $17.29 |
| Property, plant & equipment | $136.74 | $138.42 | $150.75 | $158.64 |
| Goodwill & intangible assets | $953.47 | $1185.5 | $1250.04 | $1274.58 |
| Total noncurrent assets | $1203.46 | $1419.13 | $1431.89 | $1473.88 |
| Total investments | $143.46 | $345.16 | $385.74 | $327.87 |
| Total assets | $3359.86 | $3092.17 | $2979.06 | $2957.23 |
| Current liabilities | ||||
| Accounts payable | $249.23 | $497.95 | $465.62 | $401.93 |
| Deferred revenue | ||||
| Short long term debt | $6.52 | $3.49 | $24.27 | $112.85 |
| Total current liabilities | $737.58 | $910.15 | $898.89 | $892.3 |
| Long term debt | $631.86 | $679.13 | $728.61 | $740.89 |
| Total noncurrent liabilities | $719.24 | $784.24 | $794.86 | $788.44 |
| Total debt | $638.38 | $682.62 | $752.88 | $853.74 |
| Total liabilities | $1456.82 | $1694.39 | $1693.75 | $1680.74 |
| Shareholders' equity | ||||
| Retained earnings | $1857.13 | $1475.21 | $1419.45 | $1399.49 |
| Other shareholder equity | -$0.2 | $0.14 | -$0.32 | -$0.38 |
| Total shareholder equity | $1869.97 | $1397.78 | $1285.3 | $1276.49 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1254.12 | $1220.77 | $1161.65 | $1184.96 |
| Cost of revenue | $1222.12 | $1194.82 | $1102.58 | $1181.02 |
| Gross Profit | $32 | $25.95 | $59.07 | $3.94 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $25.59 | $27.58 | $13.57 | $35.58 |
| Operating income | $6.42 | -$1.63 | $45.5 | -$31.64 |
| Income from continuing operations | ||||
| EBIT | $12.77 | $4.37 | $45.16 | $263.92 |
| Income tax expense | $0.86 | -$1.2 | $10.9 | -$11.63 |
| Interest expense | $5.97 | $6.23 | $6.43 | $6.63 |
| Net income | ||||
| Net income | $5.94 | -$0.67 | $27.83 | $268.93 |
| Income (for common shares) | $5.94 | -$0.67 | $27.83 | $268.93 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4577.53 | $7159.42 | $7314.15 | $5838.58 |
| Cost of revenue | $4458.74 | $6930.13 | $7116.97 | $5567.56 |
| Gross Profit | $118.79 | $229.29 | $197.18 | $271.02 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $132.47 | $131.51 | $132.66 | $115.71 |
| Operating income | -$13.67 | $97.78 | $64.52 | $155.31 |
| Income from continuing operations | ||||
| EBIT | $368.67 | $116.97 | $78.59 | $161.27 |
| Income tax expense | -$44.53 | $24.91 | $19.01 | $25.08 |
| Interest expense | $30.86 | $36.15 | $35.4 | $25.98 |
| Net income | ||||
| Net income | $382.33 | $55.9 | $24.18 | $110.21 |
| Income (for common shares) | $382.33 | $55.9 | $24.18 | $110.21 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $5.94 | -$0.67 | $27.83 | $268.93 |
| Operating activities | ||||
| Depreciation | $23.67 | $22.52 | $21.42 | $30.68 |
| Business acquisitions & disposals | -$0 | -$2.37 | $915.29 | |
| Stock-based compensation | $5.97 | $6.35 | $7.06 | $6.6 |
| Total cash flows from operations | $202.74 | -$64.81 | -$77.88 | $218.81 |
| Investing activities | ||||
| Capital expenditures | -$12.89 | -$15.56 | -$19.54 | -$19.47 |
| Investments | $172.35 | $300.91 | -$487.55 | $1.54 |
| Total cash flows from investing | $159.45 | $285.35 | -$509.46 | $897.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.49 | $6.8 | $7.47 | $15.88 |
| Net borrowings | -$5.47 | -$6.73 | -$105.51 | -$5.56 |
| Total cash flows from financing | -$2.24 | $1.66 | -$100.8 | $10.06 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $359.95 | $222.2 | -$688.14 | $954.3 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | $382.33 | $55.9 | $24.18 | $110.21 |
| Operating activities | ||||
| Depreciation | $118.75 | $131.51 | $132.66 | $115.71 |
| Business acquisitions & disposals | $913.22 | -$0.73 | -$0.96 | -$232.4 |
| Stock-based compensation | $25.45 | $25.5 | $29.47 | $39.12 |
| Total cash flows from operations | $450.76 | $115.85 | $164.84 | $162.27 |
| Investing activities | ||||
| Capital expenditures | -$75.48 | -$60.4 | -$68.28 | -$57.23 |
| Investments | -$158.81 | $41.64 | -$59.2 | -$26.75 |
| Total cash flows from investing | $678.94 | -$19.49 | -$128.43 | -$316.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $64.17 | $28.58 | -$39.58 | $22.59 |
| Net borrowings | -$51.67 | -$67.51 | -$122.24 | $238.34 |
| Total cash flows from financing | $13.14 | -$43.41 | -$162.84 | $248.34 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $990.6 | $52.94 | -$126.42 | $94.22 |
News
|
Hedge Funds Are Selling Arcus Biosciences, Inc. (RCUS)
Insider Monkey via Yahoo Finance
14 Jan 2022
|
|
Centene (CNC) completes $2.2B buyout of Phoenix-based Magellan Health (MGLN) - Phoenix Business...
The Business Journals
6 Jan 2022
|
|
Magellan (MGLN) Unit to Unveil Wellbeing Program for Members
MSN News
3 Jan 2022
|
|
Why Buying Molina Healthcare (MOH) is a Prudent Move Now?
MSN News
2 Jan 2022
|
|
Centene (CNC) Receives DMHC Approval for Magellan Acquisition
Zacks via Yahoo Finance
31 Dec 2021
|
|
Centene and Magellan Satisfy All Regulatory Approvals for Completion of Acquisition Agreement
WFMZ Eastern Pennsylvania and Western New Jersey
31 Dec 2021
|
|
Why Buying Molina Healthcare (MOH) is a Prudent Move Now?
Zacks via Yahoo Finance
28 Dec 2021
|
|
Magellan (MGLN) Unit Ties Up to Offer Solution for Older Adults
MSN News
26 Dec 2021
|
|
Magellan (MGLN) Unit Ties Up to Offer Solution for Older Adults
Zacks via Yahoo Finance
21 Dec 2021
|
|
New Strong Sell Stocks for December 20th
Zacks via Yahoo Finance
20 Dec 2021
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 26.33M |
| Revenue | $4.82B |
|---|---|
| EBITDA | $424.52M |
| EBIT | $326.22M |
| Net Income | $302.03M |
| Revenue Q/Q | 7.18% |
| Revenue Y/Y | -17.82% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 73.44 |
| Cash/Share | 39.44 |
| EPS | $11.47 |
|---|---|
| ROA | 9.17% |
| ROE | 15.82% |
| Debt/Equity | 0.78 |
|---|---|
| Net debt/EBITDA | 0.81 |
| Current ratio | 2.92 |
| Quick ratio | 2.86 |